Favipiravir

259793-96-9

157.10

H2O : 6.25 mg/mL (39.78 mM; Need ultrasonic); DMSO : >= 100 mg/mL (636.54 mM)

Cell Cycle/DNA Damage; Anti-infection; Anti-infection

Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5?-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM. IC50 & Target: IC50: 341 nM (RdRP)^[1] In Vitro: Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase alpha, beta or gamma with IC₅₀>1 mM. The IC₅₀ for the human RNA polymerase II is 905 uM; Favipiravir is therefore 2, 650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis^[1]. Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC₅₀: 250+/-11 uM) and MNV RNA synthesis in cell culture (EC₅₀:124+/-42 uM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 ug/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%)^[2]. In Vivo: Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive^[1].

Please note, this is not a medicine. There is no sale to doctors, pharmacies or private persons!